当前位置： SCI文献检索 > JOURNAL OF MEDICAL VIROLOGY期刊下所有文献 > Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.

Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.

Abstract：

:Oral DAA have demonstrated high efficacy as treatment of hepatitis C. However, the presence of resistance-associated substitutions (RAS) at baseline has occasionally been associated with impaired treatment response. Herein, we examined the impact of baseline RAS at the HCV NS5A gene region on treatment response in a real-life setting. All hepatitis C patients treated with DAA including NS5A inhibitors at our institution were retrospectively examined. The virus NS5A gene was analyzed using population sequencing at baseline and after 24 weeks of completing therapy in all patients that failed. All changes recorded at positions 28, 29, 30, 31, 32, 58, 62, 92, and 93 were considered. A total of 166 patients were analyzed. HCV genotypes were as follows: G1a (31.9%), G1b (48.2%), G3 (10.2%), and G4 (9.6%). Overall, 69 (41.6%) patients were coinfected with HIV and 46.7% had advanced liver fibrosis (Metavir F3-F4). Sixty (36.1%) patients had at least one RAS at baseline, including M28A/G/T (5), Q30X (12), L31I/F/M/V (6), T58P/S (25), Q/E62D (1), A92 K (7), and Y93C/H (15). Overall, 4.8% had two or more RAS, being more frequent in G4 (12.5%) followed by G1b (6.3%) and G1a (1.9%). Of 10 (6%) patients that failed DAA therapy, five had baseline NS5A RAS. No association was found for specific baseline RAS, although changes at position 30 were more frequent in failures than cures (22.2% vs 6.4%, P = 0.074). Moreover, the presence of two or more RAS at baseline was more frequent in failures (HR: 7.2; P = 0.029). Upon failure, six patients showed emerging RAS, including Q30C/H/R (3), L31M (1), and Y93C/H (2). Baseline NS5A RAS are frequently seen in DAA-naïve HCV patients. Two or more baseline NS5A RAS were found in nearly 5% and were significantly associated to DAA failure. Therefore, baseline NS5A testing should be considered when HCV treatment is planned with NS5A inhibitors.

journal_name

J Med Virol

journal_title

Journal of medical virology

authors

Carrasco I,Arias A,Benítez-Gutiérrez L,Lledó G,Requena S,Cuesta M,Cuervas-Mons V,de Mendoza C

doi

10.1002/jmv.24971

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

532-536

issue

eissn

0146-6615

issn

1096-9071

journal_volume

pub_type

杂志文章

在线工具

Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.